blank
logo-
Call: +66 64 505 5599

MENU

Call: +66 64 505 5599
logo-
Call: +66 64 108 5544
Call: +66 64 505 5599
diabetes

Stem Cells and Type 2 Diabetes: What Research Currently Shows

Type 2 diabetes is a chronic metabolic condition that affects how the body produces and responds to insulin. Medication, nutrition, physical activity, and weight management can help control the condition, but some people continue to experience high blood sugar or require increasing doses of medication over time.

This challenge has led researchers to investigate whether regenerative medicine, including Umbilical Cord Derived Mesenchymal Stem Cells, known as UC MSCs, could support metabolic function. Early clinical findings are encouraging, particularly in relation to insulin resistance, blood sugar control, and insulin requirements. However, stem cell therapy should be considered a developing approach rather than a replacement for established diabetes care.

What Happens in Type 2 Diabetes?

Insulin is a hormone produced by beta cells in the pancreas. It helps glucose move from the bloodstream into cells, where it can be used for energy.

In type 2 diabetes, the body becomes less responsive to insulin. This is known as insulin resistance. The pancreas initially compensates by producing more insulin, but beta cell function may gradually decline. As a result, glucose remains in the bloodstream and blood sugar levels rise.

Long term exposure to high blood sugar can affect the heart, kidneys, eyes, nerves, and blood vessels. Treatment therefore involves more than lowering a single glucose reading. Physicians also consider blood pressure, cholesterol, weight, kidney function, cardiovascular risk, and the prevention of diabetes related complications.

Why Are MSCs Being Studied for Type 2 Diabetes?

Mesenchymal stromal cells, commonly called MSCs, release biological signals that may influence inflammation, immune activity, blood vessel support, and tissue repair.

Chronic low grade inflammation is associated with insulin resistance and the progression of type 2 diabetes. Researchers are studying whether the signaling activity of MSCs may help create a more supportive metabolic environment.

Potential areas of interest include:

  • Regulating inflammatory activity
  • Improving the body’s response to insulin
  • Supporting remaining pancreatic beta cell function
  • Protecting cells from oxidative stress
  • Supporting small blood vessels and tissue repair
  • Influencing metabolic signaling between organs

MSCs can be obtained from bone marrow, fat tissue, and umbilical cord tissue. UC MSCs are of particular interest because they can be collected without an invasive procedure for the recipient and expanded under controlled laboratory conditions.

MSCs are not simply expected to become new pancreatic cells after infusion. Their potential benefits are thought to come mainly from the signals they release and the way those signals interact with immune and metabolic pathways.

What Does the Clinical Evidence Show?

Clinical studies of MSCs for type 2 diabetes have examined changes in HbA1c, fasting blood glucose, insulin requirements, insulin resistance, C peptide, and time in range.

HbA1c reflects average blood sugar over the previous two to three months. C peptide helps physicians estimate how much insulin the pancreas is still producing. Time in range measures how often glucose remains within a selected target range during continuous glucose monitoring.

Across available studies, some patients receiving MSCs experienced improvements in HbA1c, glucose stability, insulin sensitivity, or daily insulin requirements. Research specifically involving UC MSCs has also reported encouraging changes in blood sugar control and time in range.

Systematic reviews and meta analyses generally describe MSC therapy as promising, particularly for type 2 diabetes. Reported treatment related reactions have often been mild and temporary. However, results vary among studies because researchers use different cell sources, doses, schedules, delivery methods, patient criteria, and follow up periods.

The current evidence does not show that every patient will respond in the same way. It also does not establish stem cell therapy as a cure for type 2 diabetes. Larger studies and longer follow up are needed to understand how long potential benefits may last and which patients are most likely to respond

Why Patient Selection Matters

Type 2 diabetes is not the same in every patient. One person may have significant insulin resistance while maintaining useful pancreatic function. Another may have advanced beta cell decline after living with diabetes for many years.

This difference may influence how a patient responds to an intervention intended to support metabolic function. Physicians may review:

  • Duration of diabetes
  • Current HbA1c and glucose patterns
  • Daily medication or insulin requirements
  • Remaining insulin production
  • Body weight and insulin resistance
  • Kidney, liver, and cardiovascular health
  • Active infections or other medical conditions
  • History of diabetes related complications

A physician should also consider whether current treatment has been fully optimized. Adjusting medication, nutrition, physical activity, sleep, or weight management may offer clearer benefits for some patients.

Can Stem Cell Therapy Replace Diabetes Medication?

Patients should not stop insulin, metformin, or other prescribed medication after receiving MSC therapy unless the change is directed by the treating physician.

If blood sugar improves, medication may need to be adjusted to reduce the risk of hypoglycemia. Any reduction should be based on glucose readings, HbA1c, continuous glucose monitoring when appropriate, and medical assessment.

Current diabetes treatment may include metformin, GLP 1 based therapy, SGLT2 inhibitors, insulin, or other glucose lowering medication. The selection depends on blood sugar targets, weight, kidney function, cardiovascular health, and the risk of side effects.

MSC therapy is better understood as a potential addition to a comprehensive treatment plan. It does not remove the need for nutrition, activity, medication review, or monitoring for diabetes complications.

What Should Physicians Monitor?

A responsible treatment plan should include clear measurements before and after treatment. These may include:

  • HbA1c
  • Fasting and post meal glucose
  • Time in range
  • C peptide
  • Insulin or medication requirements
  • Kidney and liver function
  • Blood pressure and cholesterol
  • Symptoms of hypoglycemia
  • Treatment related reactions

Monitoring allows physicians to distinguish measurable metabolic changes from normal daily glucose variation. It also helps them adjust medication safely when necessary.

The Future of Regenerative Medicine for Diabetes

Research into UC MSCs and type 2 diabetes is moving toward better patient selection, standardized cell preparation, appropriate dosing, and longer follow up. Scientists are also studying extracellular vesicles and other cell derived signals that may reproduce some of the biological activity of MSCs.

Current evidence provides a meaningful reason to continue this research. Some findings suggest that UC MSCs may support insulin sensitivity and glucose control in selected patients. The most responsible approach is to evaluate each person individually, set realistic goals, and combine regenerative medicine with established diabetes care.

About EDNA Wellness

EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord Derived Mesenchymal Stem Cells (UC-MSCs).

All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.

For more information or to book a consultation:
LINE: @ednawellness
WhatsApp: +66 (0) 64 505 5599
www.ednawellness.com

References

Related Posts

error:Content is protected !!
blank